Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% - Here's What Happened
Structure Therapeutics (NASDAQ:GPCR) shares fell 6.7% to $34.9410, with trading volume up 45% from the average. Analysts have mixed ratings: Guggenheim and HC Wainwright lowered target prices but maintained 'buy' ratings, while Weiss Ratings issued a 'sell' rating. The company reported a Q3 EPS of ($0.37), missing estimates. Institutional investors hold 91.78% of shares. Structure Therapeutics develops oral therapeutics for chronic diseases, with GSBR-1290 as a lead candidate for diabetes and obesity.
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) shares were down 6.7% on Tuesday . The stock traded as low as $34.92 and last traded at $34.9410. Approximately 1,337,176 shares changed hands during mid-day trading, an increase of 45% from the average daily volume of 923,250 shares. The stock had previously closed at $37.44.
Get Structure Therapeutics alerts:
Analyst Ratings Changes
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
A number of equities analysts have weighed in on GPCR shares. Guggenheim dropped their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. HC Wainwright lowered their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Lifesci Capital upgraded Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $68.67.
View Our Latest Stock Report on GPCR
Structure Therapeutics Price Performance
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
The business has a 50 day moving average of $28.17 and a 200 day moving average of $23.40. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -28.44 and a beta of -1.64.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.01). As a group, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.
Institutional Investors Weigh In On Structure Therapeutics
- Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Several hedge funds have recently bought and sold shares of the company. State of Wyoming bought a new position in shares of Structure Therapeutics during the second quarter worth $28,000. EverSource Wealth Advisors LLC lifted its holdings in Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company's stock worth $30,000 after acquiring an additional 901 shares in the last quarter. National Bank of Canada FI lifted its holdings in Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after acquiring an additional 2,766 shares in the last quarter. Assetmark Inc. grew its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after acquiring an additional 820 shares during the period. Finally, ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after acquiring an additional 3,213 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.
Structure Therapeutics Company Profile
(Get Free Report)Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
- Five stocks we like better than Structure Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Amazon Just Did This—and It Didn't End Well Last Time
- What is the NASDAQ Stock Exchange?
- Stellantis Makes a High-Stakes Bet on Jeep
- Canada Bond Market Holiday: How to Invest and Trade
- Nuclear Energy Earnings: Which Names Won and Lost in Q3
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Structure Therapeutics Right Now?
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
